Search hospitals > Michigan > Southfield

Ascension Providence Hospitals - Southfield

Claim this profile
Southfield, Michigan 48075
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
235 reported clinical trials
10 medical researchers
Photo of Ascension Providence Hospitals - Southfield in Southfield

Summary

Ascension Providence Hospitals - Southfield is a medical facility located in Southfield, Michigan. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Ascension Providence Hospitals - Southfield is involved with conducting 235 clinical trials across 321 conditions. There are 10 research doctors associated with this hospital, such as Susan E. Lyons, Adam M. Forman, Cynthia M. Vakhariya, and Howard R. Terebelo.

Area of expertise

1Cancer
Global Leader
Ascension Providence Hospitals - Southfield has run 52 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Ascension Providence Hospitals - Southfield has run 45 trials for Breast Cancer. Some of their research focus areas include:
ER positive
HER2 negative
HER2 positive

Top PIs

Clinical Trials running at Ascension Providence Hospitals - Southfield

Breast Cancer
Non-Small Cell Lung Cancer
Cancer
Lung Cancer
Multiple Myeloma
Gastric Cancer
Pancreatic Cancer
Rectal Cancer
Squamous Cell Carcinoma
Esophageal Cancer
Image of trial facility.

Sacituzumab Govitecan

for Triple-Negative Breast Cancer

This trial is testing a drug called sacituzumab govitecan-hziy, which targets and kills cancer cells. It focuses on patients with advanced triple-negative breast cancer who have limited treatment options. The drug works by attaching to cancer cells and releasing a substance that kills them. Sacituzumab govitecan-hziy is an FDA-approved treatment for metastatic triple-negative breast cancer, especially for patients who have already tried other treatments.
Recruiting4 awards Phase 3
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Support Program

for Breast Cancer

This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Ascension Providence Hospitals - Southfield?
Ascension Providence Hospitals - Southfield is a medical facility located in Southfield, Michigan. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Ascension Providence Hospitals - Southfield is involved with conducting 235 clinical trials across 321 conditions. There are 10 research doctors associated with this hospital, such as Susan E. Lyons, Adam M. Forman, Cynthia M. Vakhariya, and Howard R. Terebelo.